0000000000906125

AUTHOR

Arnaud Bianchi

showing 2 related works from this author

Redox state alteration modulates astrocyte glucuronidation.

2004

We have investigated the effects of mild oxidative conditions on drug-metabolizing enzyme activity in rat cultured astrocytes. These experimental conditions promoting an oxidative environment were obtained by short exposure to a low concentration of menadione (5 microM) for a short duration (15 min). This resulted in the rapid and transient production of reactive oxygen species (+130%), associated with a decrease in GSH cellular content (-24%), and an increase in total protein oxidation (+26%), but promoted neither PGE(2) nor NO production. This treatment induced a rapid and persistent decrease in astrocyte glucuronidation activities, which was totally prevented by N-acetyl-l-cysteine. Thes…

MaleCell SurvivalGlucuronidationApoptosisGlucuronatesOxidative phosphorylationmedicine.disease_causeProtein oxidationBiochemistryRedoxchemistry.chemical_compoundMenadionePhysiology (medical)CricetinaemedicineAnimalsProtein IsoformsRNA MessengerGlucuronosyltransferaseRats WistarPromoter Regions GeneticCells Culturedchemistry.chemical_classificationInflammationReactive oxygen speciesBase SequenceVitamin K 3GlutathioneHydrogen PeroxideMolecular biologyGlutathioneCell biologyRatschemistryAstrocytesFemaleReactive Oxygen SpeciesOxidation-ReductionOxidative stressFree radical biologymedicine
researchProduct

Development of extracellular vesicle-based medicinal products: A position paper of the group “Extracellular Vesicle translatiOn to clinicaL perspecti…

2021

International audience; Extracellular vesicles (EV) are emergent therapeutic effectors that have reached clinical trial investigation. To translate EV-based therapeutic to clinic, the challenge is to demonstrate quality, safety, and efficacy, as required for any medicinal product. EV research translation into medicinal products is an exciting and challenging perspective. Recent papers, provide important guidance on regulatory aspects of pharmaceutical development, defining EVs for therapeutic applications and critical considerations for the development of potency tests. In addition, the ISEV Task Force on Regulatory Affairs and Clinical Use of EV-based Therapeutics as well as the Exosomes C…

Quality ControlKnowledge management[SDV.BIO]Life Sciences [q-bio]/BiotechnologyBiological medicinal productsmedia_common.quotation_subjectDrug Compounding[SDV]Life Sciences [q-bio]Regulatory requirementsPharmaceutical ScienceMarketing authorizationExosomesChemistry Techniques Analytical03 medical and health sciencesExtracellular Vesicles0302 clinical medicineDrug DevelopmentDrug Stability[CHIM]Chemical SciencesHumansQuality (business)ComputingMilieux_MISCELLANEOUS030304 developmental biologymedia_commonCell-free therapySecretome0303 health sciencesClinical Trials as TopicClinical-grade EVScientific progressbusiness.industryDrug Administration RoutesExtracellular vesicleDrugs InvestigationalRegulatory affairs3. Good health[SDV.BIO] Life Sciences [q-bio]/BiotechnologyClinical trialEuropeAnalytics030220 oncology & carcinogenesisPosition paperMedicinal productsBusinessMicrovesicles
researchProduct